[	O
Prognostic	O
significance	O
of	O
cellular	B-Cell
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
in	O
the	O
course	O
of	O
chronic	B-Cancer
myeloid	I-Cancer
leukaemia	I-Cancer
]	O

INTRODUCTION	O
:	O
Increased	O
angiogenesis	O
in	O
bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	B-Cancer
myeloid	I-Cancer
leukaemia	I-Cancer
(	O
CML	B-Cancer
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	O
/	O
abl	O
protein	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	O
of	O
angiogenesis	O
which	O
principally	O
targets	O
endothelial	B-Cell
cells	I-Cell
and	O
regulates	O
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O

The	O
impact	O
of	O
elevated	O
VEGF	O
expression	O
on	O
the	O
course	O
of	O
chronic	B-Cancer
myeloid	I-Cancer
leukaemia	I-Cancer
is	O
unknown	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	O
expression	O
during	O
the	O
course	O
of	O
CML	B-Cancer
.	O

METHODS	O
:	O
We	O
studied	O
VEGF	O
expression	O
of	O
85	O
CML	B-Cancer
patients	O
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O

At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	O
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O

The	O
temporal	O
expression	O
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	B-Cell
)	O
VEGF	O
proteins	O
over	O
the	O
course	O
of	O
CML	B-Cancer
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	O
,	O
WBC	B-Cell
and	O
platelet	B-Cell
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O

RESULTS	O
:	O
The	O
expression	O
ofVEGF	O
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
level	O
of	O
VEGF	O
expression	O
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	B-Pathological_formation
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

High	O
expression	O
of	O
VEGF	O
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O

CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	O
of	O
VEGF	O
in	O
dependence	O
of	O
the	O
CML	B-Cancer
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	B-Cancer
and	O
that	O
VEGF	O
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	B-Cancer
.	O

